Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Stipple Bio $100 million Series A

Lucid Diligence Brief: Stipple Bio $100 million Series A Professional audiences…


Lucid Diligence Brief - Tech

Lucid Diligence Brief: Syneron Bio completion of $150 million Series B

Lucid Diligence Brief: Syneron Bio completion of $150 million Series B…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Eli Lilly acquires Centessa Pharmaceuticals

Lucid Diligence Brief: Eli Lilly acquires Centessa Pharmaceuticals Professional…


Lucid Diligence Brief - Tech

Lucid Diligence Brief: CellCarta and Pillar Biosciences strategic partnership

Lucid Diligence Brief: CellCarta and Pillar Biosciences strategic partnership…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Ambrosia Biosciences $100M Series B for oral GLP-1 asset

Lucid Diligence Brief: Ambrosia Biosciences $100M Series B for oral GLP-1……


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Royalty Pharma and J&J partner in a $500M R&D deal for JNJ-4804

Lucid Diligence Brief: Royalty Pharma and J&J partner in a $500M R&D…


Artificial_Intelligence

AI in Healthcare and Digital Health Today—March 30, 2026

This week’s Artificial Intelligence and Digital Health update highlights…


Lucid Diligence Brief - Tech

Lucid Diligence Brief: InSilico Medicine and Lilly global partnership

Lucid Diligence Brief: InSilico Medicine and Lilly global partnership…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Otsuka to acquire Transcend Therapeutics

Lucid Diligence Brief: Otsuka to acquire Transcend Therapeutics Professional…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: AstraZeneca's tozorakimab meets primary endpoint in COPD

Lucid Diligence Brief: AstraZeneca's tozorakimab meets primary endpoint in……


Lucid Diligence Brief - Tech

Lucid Diligence Brief: Pinnacle Medicines $89 million Series B

Lucid Diligence Brief: Pinnacle Medicines $89 million Series B Professional…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: MSD to acquire Terns

Lucid Diligence Brief: MSD to acquire Terns Professional audiences only. Not…


Privacy Preference Center